Document Detail


Recruitment of quiescent tumor by humoral stimulatory activity: requirements for successful chemotherapy.
MedLine Citation:
PMID:  7159763     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute leukemia is a heterogeneous tumor with respect to cellular proliferation and is sensitive to positive and negative growth control factors. Tumor associated inhibitory activity (TAIA) and simultaneously present humoral stimulatory activity (HSA) in this disease may be modulated by timed sequential chemotherapy to increase tumor growth at a predictable time and make it more sensitive to accurately administered drug. Our in vivo studies of timed sequential chemotherapy in human leukemia demonstrate than an increase in tumor labeling index (LI) temporally coincides with the detection of HSA following drug administration. Maximal HSA occurs at a predictable time following initial administration of the aplasia-producing drug and is coincident with an increased LI of recovering normal marrow granulocytic elements and marrow tumor cells. These studies demonstrate the salutary effect of drugs given in high dose to reduce tumor mass and recruit tumor cells to further high-dose drug sensitivity.
Authors:
P J Burke; J E Karp; W P Vaughan; P L Sanford
Related Documents :
17854773 - Orotate phosphoribosyltransferase expression level in tumors is a potential determinant...
24133063 - Theme: physical biology in cancer. 2. the physical biology of circulating tumor cells.
16140583 - Chimeric dna vaccine reverses morphine-induced immunosuppression and tumorigenesis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Blood cells     Volume:  8     ISSN:  0340-4684     ISO Abbreviation:  Blood Cells     Publication Date:  1982  
Date Detail:
Created Date:  1983-04-15     Completed Date:  1983-04-15     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7513567     Medline TA:  Blood Cells     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  519-33     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Animals
Cell Division / drug effects
Cell Survival / drug effects
Cells, Cultured
Cytarabine / therapeutic use*
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Leukemia / drug therapy*,  pathology
Leukemia, Experimental / drug therapy
Rats
Grant Support
ID/Acronym/Agency:
CA-066973/CA/NCI NIH HHS; CA-23973/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
147-94-4/Cytarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of leukemic cell chromosomes as a guide to therapy.
Next Document:  White cell differential: coupling of cell types in patients undergoing chemotherapy.